AstraZeneca Not Interested In Acquisitions for Scale, Flat Revenues But Growing Margins
This article was originally published in The Pink Sheet Daily
Executive Summary
Little to say on Brilinta, sales momentum driven by Symbicort, Seroquel and Crestor.
You may also be interested in...
Sanofi Stays Mum On Genzyme But Near-Term M&A Appears Likely
Sanofi-Aventis is interested in acquiring a company with market cap up to $20 billion, CEO Viehbacher says, leaving open the possibility of acquiring Genzyme.
Brilinta Panel Leaves FDA With The Task Of Crafting Labeling That Describes Poor U.S Efficacy Results
FDA's Cardiovascular and Renal Drugs Advisory Committee votes 7-1 in favor of ticagrelor's approval for acute coronary syndromes despite rejecting AstraZeneca's aspirin-dosing theory as the sole cause of lack of benefit in the U.S. population.
Crestor Label Lends Validity To Controversial C-Reactive Protein Test
FDA has cleared AstraZeneca's statin Crestor for wider use in preventing heart disease and related cardiovascular events, in the process validating the controversial high sensitivity C-reactive protein test as a risk marker, some experts say